Media Release



Roche launches automated vertical transportation for U.S. patient lab samples

- The cobas[®] connection modules (CCM) Vertical including elevator and overhead conveyors to transport patient samples launches in the U.S.
- The CCM Vertical is the only clinical laboratory automation solution in the country that allows patient samples to be transported up and down, with no reduction in speed or throughput.
- Developed for labs of all sizes, the new CCM Vertical will help labs efficiently use available space by enhancing and extending existing automation layouts and providing design solutions where there wasn't one before.

INDIANAPOLIS, October 17, 2023 – Roche announced today the U.S. launch of the cobas[®] connection modules (CCM) Vertical, the elevator and overhead components of its fully automated and modular CCM system to help low-, mid- and high-volume laboratories optimize space, productivity and patient care.

"The CCM Vertical is the only laboratory conveyor system in the U.S. that moves samples up and down without reducing overall track speed, throughput or turnaround times," said Brad Moore, president and CEO, Roche Diagnostics North America. "The CCM system is about quality, flexibility and efficiency – helping labs of all sizes meet today's challenges to increase testing capacity, accelerate results, overcome staffing shortages and reduce errors."

The CCM Vertical includes elevator units, overhead conveyors and overhead turn units that seamlessly integrate with Roche's other CCM solutions. This cobas solution helps laboratorians simplify their lab operations by transporting patient samples hands-free in every direction – up, down, across and between rooms, around doorways, emergency exits and walkways, and through walls, ceilings and floors.

The first CCM Vertical implementation in the U.S. is scheduled to go live at Vanderbilt University Medical Center in early 2024.

About CCM Vertical

This solution is one of the broader laboratory-automation offerings delivered by Roche that can be customized for low-, mid- and high-volume laboratories with the ability to facilitate on-site expansion as required. With this solution, pre- and post-analytical tasks are automated, offering maximum efficiency through flexible standalone solutions. It significantly reduces manual steps in the laboratory, enhancing error handling, safety and process quality.

F. Hoffmann-La Roche Ltd

4070 Basel Switzerland

Group Communications Roche Group Media Relations Phone +41 61 688 88 88 www.roche.com



Additionally, it offers transportation. Physically connecting different instruments allows for maximum predictability of time to test results.

The solution consists of the following main (modular) components:

- Elevator units (adjustable walk-through height of 1.87-2.24 meters)
- Overhead Conveyor units
- Overhead Turntable units

A full list of Roche's laboratory-automation offerings is available <u>here</u>.

About Roche

Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalized healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In recognizing our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit <u>www.roche.com</u>.

All trademarks used or mentioned in this release are protected by law.

For further information

Roche Diagnostics U.S. Media Relations

Cindy Zinkovich (317) 931-8463 <u>cindy.zinkovich@roche.com</u> <u>us.mediarelations@roche.com</u>